For this purpose, we proposed to analyze the first progression sites of first-line TKI treatment for EGFR-mutant lung adenocarcinoma patients with systemic metastasis and then establish a radiomic-based model to predict the first progression sites, which might help to recognize the potential candidates who might benefit from radiotherapy. Here, EGFR is linked to lung adenocarcinoma.